Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. Click to read my latest analysis of IMVT stock.

A new tool at its Tisch Cancer Center helps improve accuracy, efficiency and patient access by streamlining information from the Epic EHR to clinical trial platforms.

NYU Langone’s Center for Multisite Studies is led by experts who are experienced in managing and supporting research.

This study presents a valuable finding on mutations in ZNF217, ZNF703, and ZNF750 through 23 breast cancer samples alongside matched normal tissues in Kenyan breast cancer patients. The evidence ...

Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.

At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...

Find out how an AI tool to cut costs and impact of sick calls streamlines clinical scheduling with predictive insights and human oversight.

The research, published in JAMA Health Forum, raises concerns about the FDA's current approval process of these devices and ...

Adopting the proper countermeasures to protect and maintain trust in health care data will require additional collaboration ...

New pooled data confirm that endovascular thrombectomy improves survival and function in large-core stroke, offering hope for ...

From streaming video and syncing data to connecting applications, the cloud plays an increasingly pivotal role in helping ...

One analysis showed participant costs were substantially lower – 8% below an employer client's general adult population and ...